<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025324</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068950</org_study_id>
    <secondary_id>CHLA-NYU-0007H</secondary_id>
    <secondary_id>NCI-G01-2019</secondary_id>
    <nct_id>NCT00025324</nct_id>
  </id_info>
  <brief_title>Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors</brief_title>
  <official_title>Clinical Correlative Studies In Primary Central Nervous System Germ Cell Tumors: The Third International CNS Germ Cell Tumor Study Group Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
      Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy, surgery, radiation&#xD;
      therapy, and bone marrow or peripheral stem cell transplantation in treating patients who&#xD;
      have primary CNS germ cell tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the two-year event-free survival of patients with primary CNS germ cell tumors&#xD;
           treated with carboplatin, etoposide, cyclophosphamide, and filgrastim (G-CSF) with or&#xD;
           without radiotherapy and/or high-dose chemotherapy with autologous bone marrow or&#xD;
           peripheral blood stem cell transplantation.&#xD;
&#xD;
        -  Determine the prognostic significance of slow-responding tumor marker normalization in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the prognostic significance of syncytiotrophoblastic giant cell component and&#xD;
           cerebrospinal fluid beta-human chorionic gonadotropin elevation in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Assess the early and late endocrinologic, neuropsychometric, and quality of life&#xD;
           sequelae in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to risk status (low&#xD;
      vs intermediate or high).&#xD;
&#xD;
      Regimen A (Low-risk patients)&#xD;
&#xD;
        -  Chemotherapy: Patients receive carboplatin IV over 4 hours and etoposide IV over 2 hours&#xD;
           on days 1-2 and filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 3 and&#xD;
           continuing until blood counts recover (course 1). Patients also receive cyclophosphamide&#xD;
           IV over 1 hour and etoposide IV over 2 hours on days 22 and 23 and G-CSF SC once daily&#xD;
           beginning on day 24 and continuing until blood counts recover (course 2).&#xD;
&#xD;
        -  Patients with complete response (CR) to initial chemotherapy receive 2 additional&#xD;
           courses of chemotherapy as above and then proceed to observational phase. Patients with&#xD;
           partial response (PR) to initial chemotherapy receive 2 additional courses of&#xD;
           chemotherapy as above.&#xD;
&#xD;
        -  Patients with CR after additional chemotherapy receive another 2 additional courses of&#xD;
           chemotherapy as above and then proceed to observational phase. Patients with PR after&#xD;
           additional chemotherapy undergo biopsy and/or resection of residual tumor.&#xD;
&#xD;
        -  Patients with evidence of malignant germ cell tumor (GCT) on resection undergo&#xD;
           radiotherapy. Patients with no evidence of malignant GCT on resection but with scar,&#xD;
           fibrosis, or mature teratoma receive 2 additional courses of chemotherapy as above and&#xD;
           then proceed to observational phase. Patients with no evidence of malignant GCT on&#xD;
           resection but with immature teratoma receive carboplatin IV over 4 hours,&#xD;
           cyclophosphamide IV over 1 hour, and etoposide IV over 2 hours on days 1-2 and 22-23.&#xD;
           Patients who underwent complete resection of residual tumor proceed to observational&#xD;
           phase. Patients who underwent a biopsy only or an incomplete resection of residual tumor&#xD;
           undergo radiotherapy.&#xD;
&#xD;
      Regimen B (Intermediate and high-risk patients)&#xD;
&#xD;
        -  Patients receive carboplatin IV over 4 hours, cyclophosphamide IV over 1 hour, and&#xD;
           etoposide IV over 2 hours on days 0-1. Patients also receive G-CSF SC once daily&#xD;
           beginning on day 2 and continuing until blood counts recover. Treatment repeats every 21&#xD;
           days for a total of 2 courses. Patients undergo bone marrow or peripheral blood stem&#xD;
           cell harvest prior to second course of chemotherapy.&#xD;
&#xD;
        -  Patients with rapid CR to 2 initial courses of chemotherapy receive an additional 2&#xD;
           courses of chemotherapy as above and then proceed to observational phase. Patients with&#xD;
           a PR or slow response to 2 initial courses of chemotherapy receive 2 additional courses&#xD;
           of chemotherapy as above. Patients with a CR to courses 3 and 4 receive 2 more courses&#xD;
           of chemotherapy and then proceed to observational phase. Patients with a PR to courses 3&#xD;
           and 4 undergo a biopsy and/or resection of residual tumor.&#xD;
&#xD;
        -  Patients with no evidence of malignant GCT on resection but with scar, fibrosis, or&#xD;
           mature teratoma receive carboplatin IV over 4 hours and etoposide IV over 2 hours on&#xD;
           days 1 and 2 and cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days&#xD;
           22 and 23 and proceed to observational phase. Patients with teratoma on resection&#xD;
           receive additional treatment as in regimen A. Patients with evidence of pure germinoma&#xD;
           on resection undergo radiotherapy.&#xD;
&#xD;
        -  Patients with evidence of other malignant GCT on resection undergo high-dose&#xD;
           chemotherapy (HDCx) with bone marrow or peripheral blood stem cell support (PBSCS)&#xD;
           comprising thiotepa IV over 3 hours and etoposide IV over 1 hour on days -8 through -6;&#xD;
           carboplatin IV over 4 hours on days -5 through -3; reinfusion of autologous bone marrow&#xD;
           or peripheral blood stem cells on day 0; and G-CSF SC or IV every 12 hours beginning on&#xD;
           day 1 and continuing until blood counts recover. Patients then undergo radiotherapy.&#xD;
&#xD;
      Quality of life is assessed before bone marrow or PBSCS and then every 2 years thereafter.&#xD;
&#xD;
      Patients are followed at day 42, at 3 months, then every 3 months for 1 year, every 4 months&#xD;
      for 1 year, every 6 months for 3 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (40 per stratum) will be accrued for this study&#xD;
      within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed newly diagnosed primary CNS germ cell tumor OR&#xD;
&#xD;
          -  Serum or cerebrospinal fluid (CSF) elevation of alpha-fetoprotein (AFP) or beta-human&#xD;
             chorionic gonadotropin (beta-HCG) greater than 50 ng/mL&#xD;
&#xD;
          -  Low-risk disease:&#xD;
&#xD;
               -  Histologically proven pure germinoma&#xD;
&#xD;
               -  Localized, nonmetastatic disease&#xD;
&#xD;
               -  Normal CSF&#xD;
&#xD;
               -  Normal serum tumor markers&#xD;
&#xD;
          -  Intermediate-risk disease:&#xD;
&#xD;
               -  Histologically proven germinoma&#xD;
&#xD;
               -  Beta-HCG-positive syncytiotrophoblastic giant cell component AND/OR&#xD;
&#xD;
               -  CSF elevation of beta-HCG to less than 50 ng/mL&#xD;
&#xD;
          -  High-risk disease:&#xD;
&#xD;
               -  Histologically proven choriocarcinoma, endodermal sinus tumor, or embryonal&#xD;
                  carcinoma&#xD;
&#xD;
               -  Elevated serum and/or CSF AFP OR&#xD;
&#xD;
               -  Elevated serum beta-HCG OR&#xD;
&#xD;
               -  Elevated CSF beta-HCG greater than 50 ng/mL OR&#xD;
&#xD;
               -  Disseminated disease by MRI and/or CSF cytology&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  Indirect hyperbilirubinemia due to Gilbert's syndrome is allowed&#xD;
&#xD;
          -  AST and ALT less than 5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac function normal by echocardiogram&#xD;
&#xD;
          -  No myocardial infarction or ischemia in patients over 30 years&#xD;
&#xD;
          -  Fractional shortening greater than 30%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No unacceptable morbidity of organ systems outside the CNS&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids administered solely for antiemesis during study&#xD;
             chemotherapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior cranial radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan L. Finlay, MB, ChB</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2004</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

